Research & Literature

Recognition and Management of Individuals With Hyperglycemia Because of a Heterozygous Glucokinase Mutation.

Chakera AJ, Steele AM, Gloyn AL, et al.

Diabetes care 2015; (38(7)):1383-92 doi:10.2337/dc14-2769.

[Hepatocyte nuclear factor 1α-inactivated hepatocellular adenomatosis in a patient with maturity-onset diabetes of the young type 3: case report and literature review].

Hirata E, Shimizu S, Umeda S, et al.

Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 2015; (112(9)):1696-704 doi:10.11405/nisshoshi.112.1696.

Comment on Rudland et al. Identifying Glucokinase Monogenic Diabetes in a Multiethnic Gestational Diabetes Mellitus Cohort: New Pregnancy Screening Criteria and Utility of HbA1c. Diabetes Care 2016;39:50-52.

Bhargava A, Siddiqui S, Waghdhare S, Jha S

Diabetes care 2016; (39(1)):e6 doi:10.2337/dc15-1537.

[Maturity onset diabetes of the young (MODY) - screening, diagnostic and therapy].

Kaser S, Resl M

Wiener klinische Wochenschrift 2016; (128 Suppl 2()):S204-7 doi:10.1007/s00508-015-0938-9.

GCK-MODY in the US National Monogenic Diabetes Registry: frequently misdiagnosed and unnecessarily treated.

Carmody D, Naylor RN, Bell CD, et al.

Acta diabetologica 2016; (53(5)):703-8 doi:10.1007/s00592-016-0859-8.

Maturity-Onset Diabetes of the Young (MODY): Making the Right Diagnosis to Optimize Treatment.

Amed S, Oram R

Canadian journal of diabetes 2016; (40(5)):449-454 doi:10.1016/j.jcjd.2016.03.002.

Prolonged episodes of hypoglycaemia in HNF4A-MODY mutation carriers with IGT. Evidence of persistent hyperinsulinism into early adulthood.

Bacon S, Kyithar MP, Condron EM, et al.

Acta diabetologica 2016; (53(6)):965-972 doi:10.1007/s00592-016-0890-9.

Monogenic Diabetes Accounts for 6.3% of Cases Referred to 15 Italian Pediatric Diabetes Centers During 2007 to 2012.

Delvecchio M, Mozzillo E, Salzano G, et al.

The Journal of clinical endocrinology and metabolism 2017; (102(6)):1826-1834 doi:10.1210/jc.2016-2490.

Clinical heterogeneity of type 1 diabetes (T1D) found in Asia.

Park Y, Wintergerst KA, Zhou Z

Diabetes/metabolism research and reviews 2017; (33(7)) doi:10.1002/dmrr.2907.

Management of sulfonylurea-treated monogenic diabetes in pregnancy: implications of placental glibenclamide transfer.

Shepherd M, Brook AJ, Chakera AJ, Hattersley AT

Diabetic medicine : a journal of the British Diabetic Association 2017; (34(10)):1332-1339 doi:10.1111/dme.13388.

Comprehensive screening for monogenic diabetes in 89 Japanese children with insulin-requiring antibody-negative type 1 diabetes.

Ushijima K, Fukami M, Ayabe T, et al.

Pediatric diabetes 2018; (19(2)):243-250 doi:10.1111/pedi.12544.

[Clinical phenotypes of hepatocyte nuclear factor 1 homeobox b-associated disease].

Wang F, Yao Y, Yang HX, et al.

Zhonghua er ke za zhi = Chinese journal of pediatrics 2017; (55(9)):658-662 doi:10.3760/cma.j.issn.0578-1310.2017.09.006.

The unique clinical spectrum of maturity onset diabetes of the young type 3.

Lebenthal Y, Fisch Shvalb N, Gozlan Y, et al.

Diabetes research and clinical practice 2018; (135()):18-22 doi:10.1016/j.diabres.2017.10.024.

17q12 Deletion Syndrome as a Rare Cause for Diabetes Mellitus Type MODY5.

Roehlen N, Hilger H, Stock F, et al.

The Journal of clinical endocrinology and metabolism 2018; (103(10)):3601-3610 doi:10.1210/jc.2018-00955.

Genetic causes and treatment of neonatal diabetes and early childhood diabetes.

Barbetti F, D'Annunzio G

Best practice & research. Clinical endocrinology & metabolism 2018; (32(4)):575-591 doi:10.1016/j.beem.2018.06.008.

Traditional clinical criteria outperform high-sensitivity C-reactive protein for the screening of hepatic nuclear factor 1 alpha maturity-onset diabetes of the young among young Asians with diabetes.

Rama Chandran S, Bhalshankar J, Farhad Vasanwala R, et al.

Therapeutic advances in endocrinology and metabolism 2018; (9(9)):271-282 doi:10.1177/2042018818776167.

Comprehensive genetic screening: The prevalence of maturity-onset diabetes of the young gene variants in a population-based childhood diabetes cohort.

Johnson SR, Ellis JJ, Leo PJ, et al.

Pediatric diabetes 2019; (20(1)):57-64 doi:10.1111/pedi.12766.

A UK nationwide prospective study of treatment change in MODY: genetic subtype and clinical characteristics predict optimal glycaemic control after discontinuing insulin and metformin.

Shepherd MH, Shields BM, Hudson M, et al.

Diabetologia 2018; (61(12)):2520-2527 doi:10.1007/s00125-018-4728-6.

In silico and in vitro analyses of the pathological relevance of the R258H mutation of hepatocyte nuclear factor 4α identified in maturity-onset diabetes of the young type 1.

Sugawara K, Nomura K, Okada Y, et al.

Journal of diabetes investigation 2019; (10(3)):680-684 doi:10.1111/jdi.12960.

Autoantibodies against ZnT8 are rare in Central-European LADA patients and absent in MODY patients, including those positive for other autoantibodies.

Heneberg P, Šimčíková D, Čecháková M, et al.

Journal of diabetes and its complications 2019; (33(1)):46-52 doi:10.1016/j.jdiacomp.2018.10.004.

Zinc Transporter 8 Autoantibodies (ZnT8A) and a Type 1 Diabetes Genetic Risk Score Can Exclude Individuals With Type 1 Diabetes From Inappropriate Genetic Testing for Monogenic Diabetes.

Patel KA, Weedon MN, Shields BM, et al.

Diabetes care 2019; (42(2)):e16-e17 doi:10.2337/dc18-0373.

Targeted next generation sequencing in patients with maturity-onset diabetes of the young (MODY).

Özdemir TR, Kırbıyık Ö, Dündar BN, et al.

Journal of pediatric endocrinology & metabolism : JPEM 2018; (31(12)):1295-1304.

Frequency and Characteristics of MODY 1 (HNF4A Mutation) and MODY 5 (HNF1B Mutation): Analysis From the DPV Database.

Warncke K, Kummer S, Raile K, et al.

The Journal of clinical endocrinology and metabolism 2019; (104(3)):845-855 doi:10.1210/jc.2018-01696.

Identification and functional analysis of GCK gene mutations in 12 Chinese families with hyperglycemia.

Wang Z, Diao C, Liu Y, et al.

Journal of diabetes investigation 2019; (10(4)):963-971 doi:10.1111/jdi.13001.

A rare case of congenital hyperinsulinism (CHI) due to dual genetic aetiology involving HNF4A and ABCC8.

Apperley L, Giri D, Houghton JAL, et al.

Journal of pediatric endocrinology & metabolism : JPEM 2019; (32(3)):301-304 doi:10.1515/jpem-2018-0389.

Liver adenomatosis in patients with hepatocyte nuclear factor-1 alpha maturity onset diabetes of the young (HNF1A-MODY): Clinical, radiological and pathological characteristics in a French series.

Haddouche A, Bellanne-Chantelot C, Rod A, et al.

Journal of diabetes 2020; (12(1)):48-57 doi:10.1111/1753-0407.12959.

Diagnosis and management of glucokinase monogenic diabetes in pregnancy: current perspectives.

Rudland VL

Diabetes, metabolic syndrome and obesity : targets and therapy 2019; (12()):1081-1089 doi:10.2147/DMSO.S186610.

How Recent Advances in Genomics Improve Precision Diagnosis and Personalized Care of Maturity-Onset Diabetes of the Young.

Vaxillaire M, Froguel P, Bonnefond A

Current diabetes reports 2019; (19(9)):79 doi:10.1007/s11892-019-1202-x.

Novel insights into genetics and clinics of the HNF1A-MODY.

Valkovicova T, Skopkova M, Stanik J, Gasperikova D

Endocrine regulations 2019; (53(2)):110-134.

Heterozygous lys169Glu mutation of glucokinase gene in a Chinese family having glucokinase-maturity-onset diabetes of the young (GCK-MODY).

Zhou W, Chen M, Zhou H, Zhang Z

Journal of postgraduate medicine 2019; (65(4)):241-243 doi:10.4103/jpgm.JPGM_166_19.

Next generation sequencing targeted gene panel in Greek MODY patients increases diagnostic accuracy.

Tatsi EB, Kanaka-Gantenbein C, Scorilas A, et al.

Pediatric diabetes 2020; (21(1)):28-39 doi:10.1111/pedi.12931.

Absence of Islet Autoantibodies and Modestly Raised Glucose Values at Diabetes Diagnosis Should Lead to Testing for MODY: Lessons From a 5-Year Pediatric Swedish National Cohort Study.

Carlsson A, Shepherd M, Ellard S, et al.

Diabetes care 2020; (43(1)):82-89 doi:10.2337/dc19-0747.

Maturity-onset diabetes of the young: From a molecular basis perspective toward the clinical phenotype and proper management.

Oliveira SC, Neves JS, Pérez A, Carvalho D

Endocrinologia, diabetes y nutricion 2020; (67(2)):137-147 doi:10.1016/j.endinu.2019.07.012.

Optimal Glycemic Control in a Patient With HNF1A MODY With GLP-1 RA Monotherapy: Implications for Future Therapy.

Fantasia KL, Steenkamp DW

Journal of the Endocrine Society 2019; (3(12)):2286-2289 doi:10.1210/js.2019-00278.

Patient perspectives on the diagnostic journey to a monogenic diabetes diagnosis: Barriers and facilitators.

Guan Y, Maloney KA, Pollin TI

Journal of genetic counseling 2020; (29(6)):1106-1113 doi:10.1002/jgc4.1247.

Genotype-Phenotype Characteristics of Turkish Children With Glucokinase Mutations Associated Maturity-Onset Diabetes of the Young.

Bolu S, Eroz R, Dogan M, et al.

Indian pediatrics 2020; (57(11)):1037-1039.

Treatment Options for MODY Patients: A Systematic Review of Literature.

Delvecchio M, Pastore C, Giordano P

Diabetes therapy : research, treatment and education of diabetes and related disorders 2020; (11(8)):1667-1685 doi:10.1007/s13300-020-00864-4.

Quality of Life and Treatment Satisfaction in Participants with Maturity-Onset Diabetes of the Young: A Comparison to Other Major Forms of Diabetes.

Dusatkova P, Pavlikova M, Spirkova A, et al.

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 2022; (130(2)):85-93 doi:10.1055/a-1200-1482.

Maturity-onset diabetes of the young type 5 a MULTISYSTEMIC disease: a CASE report of a novel mutation in the HNF1B gene and literature review.

Mateus JC, Rivera C, O'Meara M, et al.

Clinical diabetes and endocrinology 2020; (6()):16 doi:10.1186/s40842-020-00103-6.

Clinical implications of the glucokinase impaired function - GCK MODY today.

Hulín J, Škopková M, Valkovičová T, et al.

Physiological research 2020; (69(6)):995-1011 doi:10.33549/physiolres.934487.

Diagnosis of hepatic nuclear factor 1A monogenic diabetes mellitus (HNF1A-MODY) impacts antihyperglycemic treatment.

Schnedl WJ, Holasek SJ, Schenk M, et al.

Wiener klinische Wochenschrift 2021; (133(5-6)):241-244 doi:10.1007/s00508-020-01770-2.

Localized increases in CEPT1 and ATGL elevate plasmalogen phosphatidylcholines in HDLs contributing to atheroprotective lipid profiles in hyperglycemic GCK-MODY.

Wang X, Lam SM, Cao M, et al.

Redox biology 2021; (40()):101855 doi:10.1016/j.redox.2021.101855.

Insights into the etiology and physiopathology of MODY5/HNF1B pancreatic phenotype with a mouse model of the human disease.

Quilichini E, Fabre M, Nord C, et al.

The Journal of pathology 2021; (254(1)):31-45 doi:10.1002/path.5629.

Monogenic diabetes: a gateway to precision medicine in diabetes.

Zhang H, Colclough K, Gloyn AL, Pollin TI

The Journal of clinical investigation 2021; (131(3)).

Treatment implications of a delayed diagnosis of maturity-onset diabetes of the young.

Ali AS, Brown F, Ekinci EI

Internal medicine journal 2021; (51(1)):116-120 doi:10.1111/imj.15157.

Frequency and characterization of mutations in genes in a large cohort of patients referred to MODY registry.

Breidbart E, Deng L, Lanzano P, et al.

Journal of pediatric endocrinology & metabolism : JPEM 2021; (34(5)):633-638 doi:10.1515/jpem-2020-0501.

A Clinical Prediction Model to Distinguish Maturity-Onset Diabetes of the Young From Type 1 and Type 2 Diabetes in the Chinese Population.

Fu J, Ping F, Wang T, et al.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2021; (27(8)):776-782 doi:10.1016/j.eprac.2021.05.002.

Decreased GLUT2 and glucose uptake contribute to insulin secretion defects in MODY3/HNF1A hiPSC-derived mutant β cells.

Low BSJ, Lim CS, Ding SSL, et al.

Nature communications 2021; (12(1)):3133 doi:10.1038/s41467-021-22843-4.

NGS Analysis Revealed Digenic Heterozygous GCK and HNF1A Variants in a Child with Mild Hyperglycemia: A Case Report.

Iafusco F, Maione G, Mazzaccara C, et al.

Diagnostics (Basel, Switzerland) 2021; (11(7)) doi:10.3390/diagnostics11071164.

Molecular Diagnosis of Monogenic Diabetes and Their Clinical/Laboratory Features in Turkish Children

Gökşen D, Yeşilkaya E, Özen S, et al.

Journal of clinical research in pediatric endocrinology 2021; (13(4)):433-438 doi:10.4274/jcrpe.galenos.2021.2021.0056.

Monogenic diabetes caused by GCK gene mutation is misdiagnosed as gestational diabetes - A multicenter study in Portugal.

Lima Ferreira J, Voss G, Sá Couto A, Príncipe RM

Diabetes & metabolic syndrome 2021; (15(5)):102259 doi:10.1016/j.dsx.2021.102259.

C-peptide and residual β-cell function in pediatric diabetes - state of the art.

Jamiołkowska-Sztabkowska M, Głowińska-Olszewska B, Bossowski A

Pediatric endocrinology, diabetes, and metabolism 2021; (27(2)):123-133 doi:10.5114/pedm.2021.107165.

Glucokinase-maturity onset diabetes mellitus in the young suggested by factory-calibrated glucose monitoring data: a case report.

Nomura N, Iizuka K, Goshima E, et al.

Endocrine journal 2022; (69(4)):473-477 doi:10.1507/endocrj.EJ21-0526.

The use of SGLT2 inhibitors in achieving glycaemic control in maturity-onset diabetes of the young type 3.

Sriravindrarajah A, Fernandes A, Wu T, Hocking S

Endocrinology, diabetes & metabolism case reports 2021; (2021()).

Pregnancy in Women With Monogenic Diabetes due to Pathogenic Variants of the Glucokinase Gene: Lessons and Challenges.

Timsit J, Ciangura C, Dubois-Laforgue D, et al.

Frontiers in endocrinology 2021; (12()):802423 doi:10.3389/fendo.2021.802423.

A novel HNF4A mutation identified in a child with maturity onset diabetes of the young.

Zhu MQ, Dai YL, Chen XF, et al.

World journal of pediatrics : WJP 2022; (18(11)):778-780 doi:10.1007/s12519-022-00512-w.

Maturity-Onset Diabetes of the Young: Rapid Evidence Review.

Kant R, Davis A, Verma V

American family physician 2022; (105(2)):162-167.

Novel HNF1A gene mutation in maturity-onset diabetes of the young: A case report.

Xu Q, Kan CX, Hou NN, Sun XD

World journal of clinical cases 2022; (10(6)):1909-1913 doi:10.12998/wjcc.v10.i6.1909.

Unusual manifestations of young woman with MODY5 based on 17q12 recurrent deletion syndrome.

Cheng Y, Zhong DP, Ren L, et al.

BMC endocrine disorders 2022; (22(1)):77 doi:10.1186/s12902-022-00989-6.

Clinical and genetic characterization and long-term evaluation of individuals with maturity-onset diabetes of the young (MODY): The journey towards appropriate treatment.

Campos Franco P, Santos de Santana L, Dantas Costa-Riquetto A, et al.

Diabetes research and clinical practice 2022; (187()):109875 doi:10.1016/j.diabres.2022.109875.

Reverse Phenotyping Maternal Cystic Kidney Disease by Diagnosis in a Newborn: Case Report and Literature Review on Neonatal Cystic Kidney Diseases.

Ruzgienė D, Sutkevičiūtė M, Burnytė B, et al.

Acta medica Lituanic 2021; (28(2)):308-316 doi:10.15388/Amed.2021.28.2.5.

Mutations in GCK May Lead to MODY2 by Reducing Glycogen Synthesis.

Li Z, Li K, Sun Y, et al.

Advanced biology 2022; (6(11)):e2200097 doi:10.1002/adbi.202200097.

The Clinical Characteristics and Gene Mutations of Maturity-Onset Diabetes of the Young Type 5 in Sixty-One Patients.

Ge S, Yang M, Cui Y, et al.

Frontiers in endocrinology 2022; (13()):911526 doi:10.3389/fendo.2022.911526.

Reduced calcium levels and accumulation of abnormal insulin granules in stem cell models of HNF1A deficiency.

González BJ, Zhao H, Niu J, et al.

Communications biology 2022; (5(1)):779 doi:10.1038/s42003-022-03696-z.

Case Report: A case of HNF1B mutation patient with first presentation of diabetic ketosis.

Ge S, Yang M, Gong W, et al.

Frontiers in endocrinology 2022; (13()):917819 doi:10.3389/fendo.2022.917819.

Dorzagliatin, a Dual-Acting Glucokinase Activator, Increases Insulin Secretion and Glucose Sensitivity in Glucokinase Maturity-Onset Diabetes of the Young and Recent-Onset Type 2 Diabetes.

Chow E, Wang K, Lim CKP, et al.

Diabetes 2023; (72(2)):299-308 doi:10.2337/db22-0708.

GCK-MODY in pregnancy: A pregnant woman with diabetes and a small-for-gestational-age fetus.

Yau TTL, Yu SCY, Cheng JY, et al.

Clinical case reports 2022; (10(12)):e6629 doi:10.1002/ccr3.6629.

A Case of Diabetes Mellitus Type MODY5 as a Feature of 17q12 Deletion Syndrome

Yaşar Köstek H, Özgüç Çömlek F, Gürkan H, et al.

Journal of clinical research in pediatric endocrinology 2024; (16(2)):205-210 doi:10.4274/jcrpe.galenos.2022.2022-3-2.

A clinical mutation in glucokinase causing maturity-onset diabetes in the young type 2 increases enzyme activity.

Aránguiz O, Rivera R, Durruty P, et al.

FEBS letters 2023; (597(11)):1469-1478 doi:10.1002/1873-3468.14561.

C.487C>T mutation in PAX4 gene causes MODY9: A case report and literature review.

Zhang D, Chen C, Yang W, et al.

Medicine 2022; (101(51)):e32461 doi:10.1097/MD.0000000000032461.

Diagnosis, treatment and disclosure: A qualitative exploration of participant challenges in a Monogenic Diabetes Registry.

Noohi F, Sundaresan MS, Naylor RN, Ross LF

Genetics in medicine : official journal of the American College of Medical Genetics 2023; (25(4)):100019 doi:10.1016/j.gim.2023.100019.

Maturity-onset Diabetes of the Young Type 7 (MODY7) and the Krüppellike Factor 11 Mutation (KLF11). A Review.

Mancera-Rincón P, Luna-España MC, Rincon O, et al.

Current diabetes reviews 2024; (20(1)):e210323214817 doi:10.2174/1573399819666230321114456.

Bringing precision medicine to the management of pregnancy in women with glucokinase-MODY: a study of diagnostic accuracy and feasibility of non-invasive prenatal testing.

Hughes AE, Houghton JAL, Bunce B, et al.

Diabetologia 2023; (66(11)):1997-2006 doi:10.1007/s00125-023-05982-9.

Two novel GCK mutations in Chinese patients with maturity-onset diabetes of the young.

Wang T, Zhu M, Wang Y, et al.

Endocrine 2024; (83(1)):92-98 doi:10.1007/s12020-023-03509-1.

Glucokinase Variant Proteins Are Resistant to Fasting-Induced Uridine Diphosphate Glucose-Dependent Degradation in Maturity-Onset Diabetes of the Young Type 2 Patients.

Cho J, Horikawa Y, Oiwa Y, et al.

International journal of molecular sciences 2023; (24(21)) doi:10.3390/ijms242115842.

Generation and characterization of an induced pluripotent stem cell (iPSC) line SDQLCHi063-A from peripheral blood mononuclear cells of a patient with Maturity-onset diabetes of the young type 2 carrying GCK exon 1 deletion.

Gao M, Li X, Lv Y, et al.

Stem cell research 2024; (77()):103389 doi:10.1016/j.scr.2024.103389.

Challenges in the management of patients with HNF1B MODY and multisystem manifestations: the cases of two adolescent boys.

Vourdoumpa A, Paltoglou G, Mertzanian A, et al.

Hormones (Athens, Greece) 2024; (23(3)):439-445 doi:10.1007/s42000-024-00580-9.

Low C-Reactive Protein Alleles in Hepatocyte Nuclear Factor 1A Are Associated With an Increased Risk of Cardiovascular Disease.

Yang C, Ji L, Han X

The Journal of clinical endocrinology and metabolism 2025; (110(2)):592-600 doi:10.1210/clinem/dgae602.

A novel nonsense mutation c.747C>G in the NEUROD1 gene detected within a Chinese family affected by maturity-onset diabetes of the young type 6.

Li Y, Wen Q, Shao H, et al.

Journal of diabetes 2024; (16(9)):e13607 doi:10.1111/1753-0407.13607.

Clinical screening for GCK-MODY in 2,989 patients from the Brazilian Monogenic Diabetes Study Group (BRASMOD) and the Brazilian Type 1 Diabetes Study Group (BrazDiab1SG).

Peixoto-Barbosa R, Calliari LE, Crispim F, et al.

Archives of endocrinology and metabolism 2024; (68()):e230314 doi:10.20945/2359-4292-2023-0314.

Investigating misclassification of type 1 diabetes in a population-based cohort of British Pakistanis and Bangladeshis using polygenic risk scores.

Liu T, Sankareswaran A, Paterson G, et al.

Scientific reports 2025; (15(1)):1168 doi:10.1038/s41598-024-80348-8.

Efficacy and safety of SGLT2 inhibitors in the treatment of maturity-onset diabetes of the young (MODY): a case report and literature review.

Bombonato M, Beccuti G, Benso A, et al.

Hormones (Athens, Greece) 2025; (24(2)):495-498 doi:10.1007/s42000-025-00632-8.

Effect of SGLT2 Inhibition on Glucosuria During a Hyperglycemic Clamp in HNF1A-MODY (MODY3) and Type 2 Diabetes.

Maagensen H, Jensen JS, Høyerup SO, et al.

Diabetes care 2025; (48(9)):1536-1544 doi:10.2337/dc25-0737.

Pregnancy and Neonatal Outcomes in Maturity-Onset Diabetes of the Young: A Systematic Review.

Ługowski F, Babińska J, Makowska K, et al.

International journal of molecular sciences 2025; (26(13)) doi:10.3390/ijms26136057.

Additive Effects of Dorzagliatin and Glucagon-Like Peptide 1 Receptor Agonism in a Novel Mouse Model of GCK-MODY and in Obese db/db Mice.

Salazar S, Delgadillo-Silva LF, Carapeto P, et al.

Diabetes 2026; (75(1)):99-114 doi:10.2337/db25-0520.

PDX-1 related diabetes: a case series of two families highlighting challenges in MODY diagnosis.

da Silva BT, Pinheiro AT, Saraiva M, et al.

Acta diabetologica 2026; (63(2)):201-208 doi:10.1007/s00592-025-02614-z.

Clinical and cost-effectiveness of non-invasive cell-free DNA testing to optimise foetal outcomes for women with monogenic diabetes due to inactivating glucokinase gene mutations: a case series.

Jones AS, Kevat D, Lee IL, et al.

Internal medicine journal 2025; (55(12)):2059-2064 doi:10.1111/imj.70262.

Why all MODY variants in transcription factor genes are dominantly inherited.

Zug R

Frontiers in genetics 2025; (16()):1690468 doi:10.3389/fgene.2025.1690468.

Gliclazide Challenge Testing as an Alternative Diagnostic Tool for Hepatocyte Nuclear Factor-1-Alpha Maturity Onset Diabetes of the Young.

Pandya S, Khairati R, Mann J, et al.

European journal of case reports in internal medicine 2025; (12(12)):005892 doi:10.12890/2025_005892.

HLA-guided identification of monogenic diabetes in antibody-negative type 1 diabetes: frequency and characteristics.

Chen Y, Yin M, Xie Y, et al.

Diabetes & metabolism 2026; (52(2)):101741 doi:10.1016/j.diabet.2026.101741.

Low prevalence of GCK gene mutations in Chinese patients with gestational diabetes mellitus.

Wang Z, Huo L, Lan L, et al.

Clinics (Sao Paulo, Brazil) 2026; (81()):100889 doi:10.1016/j.clinsp.2026.100889.

Case Report: Identification of a HNF1A exons 1-10 heterozygous deletion in a Chinese MODY family.

Lei M, Xue M, Wang H, et al.

Frontiers in endocrinology 2026; (17()):1743021 doi:10.3389/fendo.2026.1743021.